Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate
Brand Name
Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate
Generic Name
Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate
Active Ingredient
EfavirenzCategory
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
Variants
7
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate, you must consult a qualified healthcare professional.
| 600 mg/1 | TABLET, FILM COATED | ORAL | 72162-2565 |
| 600 mg/1 | TABLET, FILM COATED | ORAL | 65862-497 |
| 600 mg/1 | TABLET, FILM COATED | ORAL | 42385-915 |
| 600 mg/1 | TABLET, FILM COATED | ORAL | 31722-736 |
Detailed information about Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate
Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents, functioning by blocking viral replication at the molecular level.
The standard recommended dose of Efavirenz for adults infected with HIV-1 is 600 mg taken orally once daily. This dose is almost always used in conjunction with other antiretroviral medications, such as tenofovir and emtricitabine or lamivudine. To minimize central nervous system side effects, it is strongly recommended that the dose be taken at bedtime. Taking the medication before sleep allows the peak plasma concentrations—which are associated with dizziness and confusion—to occur while the patient is asleep.
Pediatric dosing is based strictly on the child's weight. The following is a general guideline for Efavirenz capsules in children at least 3 months old:
For children who cannot swallow capsules, the capsules may be opened and the contents added to a small amount of food (like applesauce or yogurt), but this must be done carefully to ensure the full dose is consumed.
The pharmacokinetics of Efavirenz have not been extensively studied in patients with renal (kidney) failure. However, since less than 1% of Efavirenz is excreted unchanged in the urine, renal impairment is not expected to significantly impact the drug's clearance. No dosage adjustment is typically required for patients with kidney disease.
Because Efavirenz is extensively metabolized by the liver, patients with hepatic (liver) impairment must be monitored closely.
Clinical studies did not include enough subjects over 65 to determine if they respond differently. However, because elderly patients are more likely to have decreased hepatic or cardiac function, healthcare providers usually start at the lower end of the dosing range and monitor closely.
If you miss a dose of Efavirenz, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take two doses at once to make up for a missed one. Consistency is vital in HIV treatment to prevent the virus from developing resistance to the medication.
Signs of Efavirenz overdose may include increased nervous system symptoms (dizziness, confusion, vivid dreams) and involuntary muscle contractions. If an overdose is suspected, contact a poison control center or seek emergency medical attention immediately. Treatment is supportive, focusing on maintaining vital signs and monitoring the patient's neurological status. Activated charcoal may be used to help remove unabsorbed drug from the gastrointestinal tract.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to treatment failure.
Efavirenz is well-known for causing central nervous system (CNS) side effects, which affect approximately 50% of patients starting the medication. These symptoms usually appear within the first 1-2 days of therapy and typically resolve or significantly diminish after 2 to 4 weeks of continued use.
Efavirenz is a potent medication that requires strict adherence and careful monitoring. It is essential that patients do not share this medication with others and that they inform all healthcare providers (including dentists and specialists) that they are taking an NNRTI. Because Efavirenz remains in the body for a long time, its effects and potential for drug interactions can persist for weeks after the last dose is taken.
No FDA black box warnings for Efavirenz are currently mandated in the standard 'black box' format, but the 'Warnings and Precautions' section of the FDA label is exceptionally robust regarding psychiatric and hepatic risks. (Note: Older formulations or combination products like Atripla may have boxed warnings related to other components like Tenofovir and Hepatitis B exacerbation).
Efavirenz is a potent inducer of the CYP3A4 enzyme, which means it speeds up the breakdown of many other drugs, making them less effective. Conversely, some drugs can dangerously increase Efavirenz levels. The following must NEVER be used with Efavirenz:
There are specific clinical scenarios where Efavirenz must never be used due to the risk of life-threatening complications:
Efavirenz is classified as a drug that may cause fetal harm when administered during the first trimester. Historically, it was categorized as FDA Pregnancy Category D.
In the United States and other regions where clean water and infant formula are available, the CDC and FDA recommend that HIV-infected mothers do not breastfeed
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Its activity is mediated by non-competitive inhibition of the HIV-1 reverse transcriptase (RT) enzyme. It does not inhibit HIV-2 RT or human cellular DNA polymerases alpha, beta, gamma, or delta. The drug binds to a hydrophobic pocket in the p66 subunit of the HIV-1 RT heterodimer. This binding site is distinct from the substrate binding site used by NRTIs. By binding here, Efavirenz acts as a 'molecular wedge' that interferes with the flexibility of the enzyme, preventing it from catalyzing the conversion of viral RNA into DNA. This prevents the formation of the provirus and the subsequent infection of the host cell.
Common questions about Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate
Efavirenz is a prescription medication used to treat Human Immunodeficiency Virus type 1 (HIV-1) infection. It belongs to a group of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), which work by blocking a specific enzyme the virus needs to replicate. By lowering the amount of HIV in the body, Efavirenz helps the immune system work better and reduces the risk of HIV-related complications. It is always used in combination with other HIV medicines to prevent the virus from becoming resistant. It is approved for use in adults and children who meet specific weight requirements.
The most common side effects of Efavirenz involve the central nervous system and occur in about half of all patients. These include dizziness, insomnia, vivid or unusual dreams, and difficulty concentrating. Many patients also experience a mild skin rash during the first few weeks of treatment. Most of these symptoms appear within the first day or two of starting the medication and usually go away or become much less noticeable after 2 to 4 weeks. Taking the medication on an empty stomach at bedtime can significantly help reduce the severity of these side effects.
It is strongly recommended that you avoid or strictly limit alcohol consumption while taking Efavirenz. Alcohol can worsen the dizziness, confusion, and sleepiness that are common side effects of the medication, which can lead to impaired judgment or accidents. Furthermore, both Efavirenz and alcohol are processed by the liver, and combining them may increase the risk of liver damage or inflammation. If you have a history of alcohol use disorder, it is vital to discuss this with your healthcare provider before starting treatment. Always prioritize your safety and the health of your liver by minimizing alcohol intake.
The use of Efavirenz during pregnancy is a complex topic that should be discussed thoroughly with an HIV specialist. While early studies suggested a risk of birth defects like spina bifida, more recent and extensive data indicate that the risk is not significantly higher than with other HIV medications. Current guidelines generally allow for the use of Efavirenz in pregnant individuals if it is the most effective option for controlling the virus. However, if you are planning to become pregnant or find out you are pregnant while taking Efavirenz, contact your doctor immediately. Controlling the virus is essential for both your health and preventing transmission to the baby.
Efavirenz begins working at the molecular level to block HIV replication shortly after the first dose is taken. However, it takes time for this to translate into a measurable decrease in the 'viral load' in your blood. Most patients will see a significant drop in their viral load within the first 2 to 4 weeks of treatment. The ultimate goal is to reach an 'undetectable' viral load, which typically occurs within 3 to 6 months of consistent, daily use. Regular blood tests will be performed by your doctor to monitor this progress and ensure the medication is working effectively.
No, you should never stop taking Efavirenz or any other HIV medication suddenly without your doctor's explicit instructions. Stopping the medication allows the HIV virus to begin replicating again, which can lead to a rapid increase in viral load and a drop in CD4 cells (immune cells). More importantly, stopping Efavirenz alone while continuing other medications, or stopping all medications at once, can cause the virus to develop resistance. Because Efavirenz stays in your body for a long time, the virus can 'learn' how to beat it if the levels drop slowly. This could make Efavirenz and similar drugs ineffective for you in the future.
If you miss a dose of Efavirenz, take it as soon as you remember, provided it is still the same day. If you do not remember until the next day, skip the missed dose and take your next scheduled dose at the usual time. Do not take two doses at once to make up for the one you missed, as this can increase the risk of side effects. Consistency is the most important factor in HIV treatment; missing doses can allow the virus to multiply and become resistant to the drug. If you find it difficult to remember your doses, talk to your pharmacist about using a pill box or a reminder app.
Efavirenz itself is not typically associated with significant, rapid weight gain in the same way that some newer HIV medications (like certain integrase inhibitors) might be. However, many patients starting HIV therapy experience 'return-to-health' weight gain as their immune system recovers and the chronic inflammation caused by the virus decreases. Long-term use of Efavirenz has also been linked to lipodystrophy, which is a redistribution of body fat. This can involve losing fat in the face and limbs while gaining fat in the abdominal area or upper back. If you notice significant changes in your weight or body shape, discuss them with your healthcare provider.
Efavirenz has many significant drug interactions because it affects how the liver processes other medications. It can make some drugs less effective (like certain birth control pills or Hepatitis C treatments) and can cause others to build up to dangerous levels. It is critical that you provide your doctor and pharmacist with a complete list of all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements (especially St. John's Wort) that you are taking. Your doctor will check for interactions and may need to adjust your dosages or choose different medications to ensure your safety and the effectiveness of your HIV treatment.
Yes, Efavirenz is available as a generic medication in several forms, including the 600 mg tablet and various capsule strengths. Generic versions are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name version (Sustiva). They are also required to be 'bioequivalent,' meaning they work in the body the same way as the brand-name drug. Choosing a generic can often significantly reduce the cost of HIV treatment. Talk to your pharmacist or insurance provider to see if a generic version of Efavirenz is available and appropriate for you.
Other drugs with the same active ingredient (Efavirenz)
> Warning: Stop taking Efavirenz and call your doctor immediately if you experience any of these symptoms. These may indicate life-threatening reactions.
While Efavirenz does not carry a traditional 'Black Box Warning' in the same format as some other drugs (like NRTIs and lactic acidosis), it carries strong boxed warnings in its prescribing information regarding:
Report any unusual symptoms to your healthcare provider immediately. Do not wait for your next scheduled appointment if you feel your mental health is declining.
Regular laboratory monitoring is a cornerstone of Efavirenz therapy:
Because Efavirenz frequently causes dizziness, sleepiness, and impaired concentration, patients should not drive or operate heavy machinery until they are certain the medication does not affect their ability to perform these tasks safely. These effects are most common in the first few weeks of treatment.
Alcohol should be avoided or strictly limited while taking Efavirenz. Alcohol can worsen the central nervous system side effects (dizziness, confusion) and may increase the risk of liver toxicity. Combining alcohol with Efavirenz significantly increases the risk of impaired judgment and coordination.
Never stop taking Efavirenz without consulting your doctor. Sudden discontinuation can lead to 'viral rebound,' where the amount of HIV in the blood increases rapidly. Furthermore, because Efavirenz has a very long half-life, stopping it while continuing other HIV drugs with shorter half-lives can lead to the virus being exposed to Efavirenz alone, which rapidly leads to drug resistance.
> Important: Discuss all your medical conditions with your healthcare provider before starting Efavirenz, especially any history of liver disease, seizures, or mental health disorders.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Keep a current list and present it at every medical appointment.
These conditions require a careful risk-benefit analysis by a specialist:
There is no significant evidence of cross-sensitivity between Efavirenz and other classes of HIV medications (like Protease Inhibitors or Integrase Inhibitors). However, there may be a limited risk of cross-reactivity with other NNRTIs (like Nevirapine) regarding skin rashes. If a patient has had a life-threatening rash from another NNRTI, Efavirenz should be used with extreme caution or avoided.
> Important: Your healthcare provider will evaluate your complete medical history, including mental health and liver function, before prescribing Efavirenz.
Efavirenz is approved for use in children at least 3 months of age and weighing at least 3.5 kg.
Clinical experience in patients aged 65 and older is limited.
As less than 1% of the drug is excreted by the kidneys, no dose adjustment is required for patients with renal insufficiency. However, patients on dialysis should still be monitored for overall tolerance of the ART regimen.
> Important: Special populations require individualized medical assessment and frequent follow-up to ensure safety and efficacy.
| Parameter | Value |
|---|---|
| Bioavailability | Increased by 28% with high-fat meal |
| Protein Binding | 99.5% to 99.75% (Albumin) |
| Half-life | 40 to 55 hours (after multiple doses) |
| Tmax | 3 to 5 hours |
| Metabolism | Hepatic (CYP2B6, CYP3A4) |
| Excretion | Fecal (16-61%), Renal (14-34% as metabolites) |
Efavirenz is a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Related medications in this class include Nevirapine (Viramune), Delavirdine (Rescriptor), Etravirine (Intelence), Rilpivirine (Edurant), and Doravirine (Pifeltro). Efavirenz is considered a 'first-generation' NNRTI.